Does Dr. DINA ABDELWAHAB have financial conflicts of interest?

Dr. DINA ABDELWAHAB (MD) has received a total of $1,004 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $1,004 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. DINA ABDELWAHAB?

According to CMS Open Payments data, Dr. DINA ABDELWAHAB received funding from AURINIA PHARMA U.S ($267), ASTRAZENECA PHARMACEUTICALS ($221), and TAKEDA PHARMACEUTICALS U.S.A ($146).

Does Dr. DINA ABDELWAHAB receive research grants or speaking fees?

Dr. DINA ABDELWAHAB has received $1,004 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. DINA ABDELWAHAB

MDReal-Time Hydrated

Specialty: Internal Medicine, Nephrology

Practice Location: DALLAS, TX 75246

NPI Number: 1801050208

LIFETIME INDUSTRY VALUE

$1,004

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABDELWAHAB is a verified Internal Medicine, Nephrology practitioner based in DALLAS, TX.

Between 2021 and 2024, Dr. ABDELWAHAB had an overall industry promotional and research financial footprint of $1,004 as recorded in the federal CMS Open Payments database.

$1,004 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDELWAHAB's primary funding source is AURINIA PHARMA U.S, which accounts for $267 (representing 26.6% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

AURINIA PHARMA U.S

Rank 1

$267

26.6%

ASTRAZENECA PHARMACEUTICALS

Rank 2

$221

22%

TAKEDA PHARMACEUTICALS U.S.A

Rank 3

$146

14.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.